2025
Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.
Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeoadjuvant immune checkpoint inhibitorsPathological stageDMMR tumorsPMMR tumorsColon cancerSurgical resectionT stageRadiographic stagePathologic complete response rateUtilization of computed tomographyClinically staged patientsNode negative tumorsRate of understagingComplete response rateLocally advanced diseaseNode-positive diseaseClinical tumor stageNode-positive tumorsUpfront surgical resectionCorrelated to pathological stagingPrimary tumor growthLocalized colon cancerLow relapse rateEarly stage tumorsPredictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.
Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.Peer-Reviewed Original ResearchCRC-specific mortalityAll-cause mortalityCancer diagnosisColorectal cancerLong-term CRC survivorsNon-cancer related conditionsNon-metastatic colorectal cancerSEER-MedicareRisk of all-cause mortalityRecurrence of colorectal cancerColon cancerSEER-Medicare populationYear 5CRC survivorsSEER-Medicare databaseSurvivorship careRectal cancerFollow-up accountsColorectal cancer recurrenceMultiple co-morbiditiesMedicare claimsRetrospective cohort studyFine-Gray modelEstimate cumulative incidencePrimary risk factor
2024
Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer
Gupta P, Zhan P, Leeds I, Mongiu A, Reddy V, Pantel H. Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer. Journal Of Surgical Research 2024, 304: 371-382. PMID: 39615154, DOI: 10.1016/j.jss.2024.10.041.Peer-Reviewed Original ResearchLynch syndromePractice patternsCancers associated with Lynch syndromeColorectal cancerColon cancerNonmetastatic colorectal cancerDiagnosed CRC patientsMismatch repairDetect mismatch repairSurgical managementMMR-DMMR testingCRC patientsSurgical practice patternsAssociated with decreased ratesBlack raceRate of extended resectionDNA mismatch repairMismatch repair-proficient tumorsNational Cancer DatabaseNonmetastatic CRC patientsColon cancer patientsGermline mutationsCancer patientsTreatment decisionsColibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer
Agrawal R, Al-Hiyari S, Hugh-White R, Hromas R, Patel Y, Williamson E, Mootor M, Gonzalez A, Fu J, Haas R, Jordan M, Wickes B, Mohammed G, Tian M, Doris M, Jobin C, Wernke K, Pan Y, Yamaguchi T, Herzon S, Boutros P, Liss M. Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer. European Urology Oncology 2024 PMID: 39547899, DOI: 10.1016/j.euo.2024.10.015.Peer-Reviewed Original ResearchProstate cancerInduction of genomic instabilityPC diagnosisPC etiologyColibactin-producing Escherichia coliEtiology of prostate cancerProstate cancer cellsProstate cancer diagnosisSomatic point mutationsCombination in vitroGenomic instabilityAndrogen-dependentColon cancerPatient populationProstateClinical cohortInitial cancerSomatic mutationsCancer cellsDihydrotestosteroneGenetic dysfunctionSingle cell lineCancerCell linesDiagnosisMetastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties
Shin J, Park J, Lim J, Jeong J, Dinesh R, Maher S, Kim J, Park S, Hong J, Wysolmerski J, Choi J, Bothwell A. Metastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties. ELife 2024, 13 DOI: 10.7554/elife.97279.3.Peer-Reviewed Original ResearchCancer cellsDickkopf-2Promoter region of Sox9Analysis of transcriptomeGeneration of cancer cellsPositive cancer cellsStem cell niche factorsColon cancer cellsPaneth cell differentiationHepatocyte nuclear factor 4 alphaLysozyme positive cellsChromatin accessibilityHNF4A proteinSingle-cell RNA sequencing analysisCell propertiesPaneth cell markersSequence analysisChromatin immunoprecipitationPromoter regionTranscription factorsTranscriptome analysisColon cancerColon cancer metastasisReduction of liver metastasisDownstream targetsMetastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties.
Shin J, Park J, Lim J, Jeong J, Dinesh R, Maher S, Kim J, Park S, Hong J, Wysolmerski J, Choi J, Bothwell A. Metastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties. ELife 2024, 13 PMID: 39535280, PMCID: PMC11560131, DOI: 10.7554/elife.97279.Peer-Reviewed Original ResearchConceptsCancer cellsDickkopf-2Analysis of transcriptomeGeneration of cancer cellsPositive cancer cellsStem cell niche factorsColon cancer cellsPaneth cell differentiationHepatocyte nuclear factor 4 alphaLysozyme positive cellsChromatin accessibilityHNF4A proteinSingle-cell RNA sequencing analysisCell propertiesPaneth cell markersSequence analysisChromatin immunoprecipitationPromoter regionTranscription factorsTranscriptome analysisColon cancerColon cancer metastasisReduction of liver metastasisDownstream targetsCell differentiationLi-Fraumeni Syndrome: Imaging Features and Guidelines.
Gosangi B, Dixe de Oliveira Santo I, Keraliya A, Wang Y, Irugu D, Thomas R, Khandelwal A, Rubinowitz A, Bader A. Li-Fraumeni Syndrome: Imaging Features and Guidelines. RadioGraphics 2024, 44: e230202. PMID: 39024172, DOI: 10.1148/rg.230202.Peer-Reviewed Original ResearchConceptsLi-Fraumeni syndromeLifetime risk of cancerRare autosomal dominant familial cancer syndromeIncreased riskRisk of cancerTreated with total mastectomyAutosomal dominant familial cancer syndromeImaging features of tumorsFamilial cancer syndromeWhole-body MRIAnnual screeningFeatures of tumorsCancer syndromesLifetime riskP53 transcription factorLi-FraumeniAdrenocortical cancerTotal mastectomyPrimary cancerBreast malignancyImaging guidelinesBreast cancerGermline mutationsColon cancerManagement guidelinesNCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.Peer-Reviewed Original ResearchConceptsRectal cancerResponders to neoadjuvant therapyRisk of pelvic recurrenceLocally recurrent rectal cancerEarly-stage rectal cancerNonoperative management approachRecurrent rectal cancerDistal rectal cancerNCCN Guidelines InsightsCurative-intent therapyRectal cancer surgeryOptimal treatment planEndoscopic submucosal dissectionQuality of lifePelvic recurrenceNeoadjuvant therapyMultimodal therapyNCCN GuidelinesGenitourinary functionPatient selectionPoor prognosisCancer surgeryColon cancerSubmucosal dissectionClinical trialsImproved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly E, Shields A, Ogino S, Fuchs C, Meyerhardt J. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). Journal Of Clinical Oncology 2024, 42: 2853-2859. PMID: 38889377, PMCID: PMC11392453, DOI: 10.1200/jco.23.01680.Peer-Reviewed Original ResearchDisease-free survivalStage III colon cancerIII colon cancerRisk of recurrenceGain-of-function mutationsColon cancerWildtype patientsMutation statusImproved survivalUsage of COX-2 inhibitorsGain-of-functionStandard adjuvant chemotherapyCOX-2Primary end pointCyclooxygenase 2 inhibitionCOX-2 inhibitorsColorectal cancer diagnosisCOX-2 inhibitionWhole-exome sequencing dataNational Cancer InstitutePIK3CA statusOverall survivalAdjuvant chemotherapyStatistically significant improvementClinical trial updateColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Gurski L, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 38862008, DOI: 10.6004/jnccn.2024.0029.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerNCCN Clinical Practice GuidelinesSystemic therapy optionsGoal of therapyClinical practice guidelinesNCCN GuidelinesToxicity profileTherapy optionsColon cancerMutation profilesActive drugCancer deathDiagnosed cancerCancerConstituent drugsTherapyPractice guidelinesNCCNDrugTumorColorectalGuidelinesUnited StatesOncologyPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyInflammation and gut barrier function-related genes and colorectal cancer risk in western European populations
Mandle H, Jenab M, Gunter M, Tjønneland A, Olsen A, Dahm C, Zhang J, Sugier P, Rothwell J, Severi G, Kaaks R, Katzke V, Schulze M, Masala G, Sieri S, Panico S, Sacerdote C, Bonet C, Sánchez M, Amiano P, Huerta J, Guevara M, Palmqvist R, Löwenmark T, Perez-Cornago A, Weiderpass E, Heath A, Cross A, Vineis P, Hughes D, Fedirko V. Inflammation and gut barrier function-related genes and colorectal cancer risk in western European populations. Mutagenesis 2024, 40: 48-60. PMID: 38441165, PMCID: PMC11911009, DOI: 10.1093/mutage/geae008.Peer-Reviewed Original ResearchRectal cancer riskColorectal cancer riskCancer riskSingle-nucleotide polymorphismsAssociated with rectal cancer riskColorectal cancerAssociated with rectal cancerIncident CRC casesAssociated with colon cancerEuropean Prospective InvestigationSingle-nucleotide polymorphism levelColon cancerGut barrier functionUnique single-nucleotide polymorphismsNutrition CohortEuropean populationsCRC casesCrohn's diseaseUnadjusted p-valuesProspective InvestigationInvestigate associationsGene levelColorectal cancer developmentBarrier functionGut barrier permeability
2023
Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCCClinical outcomes of elective robotic vs laparoscopic surgery for colon cancer utilizing a large national database
Ahuja V, Paredes L, Leeds I, Perkal M, King J. Clinical outcomes of elective robotic vs laparoscopic surgery for colon cancer utilizing a large national database. Surgical Endoscopy 2023, 37: 7199-7205. PMID: 37365394, DOI: 10.1007/s00464-023-10215-6.Peer-Reviewed Original ResearchConceptsAnastomotic leak rateBody mass indexLarge national databaseOverall complicationsAnastomotic leakOperative timeInvasive colectomyColon cancerElective colon cancer resectionHigher body mass indexNational databaseOperating roomPost-operative lengthColon cancer resectionLonger operative timeRange of surgeryNon-Hispanic whitesCancer resectionACS-NSQIPLaparoscopic colectomyClinical outcomesMass indexLaparoscopic counterpartLaparoscopic surgeryPatient outcomesA 46-Year-Old Woman With Chronic Dyspnea and Diarrhea
Kshattry S, White M, Tchack J, Laskin W, Kunz P. A 46-Year-Old Woman With Chronic Dyspnea and Diarrhea. CHEST Journal 2023, 163: e23-e29. PMID: 36628681, DOI: 10.1016/j.chest.2022.08.2214.Peer-Reviewed Original ResearchConceptsPack-year historyCurrent tobacco usePertinent medical historyReview of systemsNew edemaAbdominal painChest painChronic dyspneaHealthy womenHot flashesRecent travelMedical historyDegree relativesFamily historyTobacco useOlder womenColon cancerHeart palpitationsMedical careWeight lossDyspneaPainDiarrheaWomenEpisodes
2022
Ethnic and Racial Inequities in Cancer Screening During the COVID-19 Pandemic: a multi-site observational study in the United States
Idossa D, Borno H, Wang K, Pletcher M, Gresham G, Canchola A, Bell D, Matheny M, Schilling L, Perkins A, Zheng K, Ohno-Machado L, Kim J, Soohoo S, Meeker D, Gomez S. Ethnic and Racial Inequities in Cancer Screening During the COVID-19 Pandemic: a multi-site observational study in the United States. International Journal Of Cancer Care And Delivery 2022, 2 DOI: 10.53876/001c.37412.Peer-Reviewed Original ResearchCancer screeningBlack individualsProstate cancer screeningSARS-CoV2 infectionColon cancer screeningMulti-site observational studyCOVID-19 pandemicRelative reductionSurgical resectionProstate resectionProstate cancerCurrent COVID-19 pandemicObservational studyColon cancerSARS-CoV2Largest relative declineLargest relative reductionInfection rateDiagnostic mammogramsDiagnostic proceduresScreening activitiesBreastStudy periodDiagnostic mammographyColonDevelopment of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer
van den Driest L, Johnson CH, Rattray NJW, Rattray Z. Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer. Alternatives To Laboratory Animals 2022, 50: 282-292. PMID: 35765262, DOI: 10.1177/02611929221107546.Peer-Reviewed Original ResearchConceptsColorectal cancerBioinformatics toolsExpression patternsKirsten rat sarcoma viral oncogene homologueNext-generation sequencing technologiesDifferential expression patternsCancer-related mortalityGenetic alterationsAdenomatous polyposis coliEffector proteinsMutational driversPrognostic significancePrognostic valueSequencing technologiesBioinformatics pipelinePatient prognosisGenetic dataB-RafColorectal tumorsNovel biomarkersColon cancerTherapeutic outcomesFrequency of mutationsAnatomical locationOncogene homologueOvercoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif T, Yibirin M, De Oliveira-Gomes D, Machaalani M, Nawfal R, Bittar G, Bahmad H, Bitar N. Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing. Cancers 2022, 14: 2105. PMID: 35565237, PMCID: PMC9099737, DOI: 10.3390/cancers14092105.Peer-Reviewed Original ResearchColorectal cancerDecreases chemotherapy toxicityTreatment of colorectal cancerOvercome therapy resistanceDevelopment of promising therapiesRates of obesityMetastatic settingChemotherapy toxicityStandard screening methodTherapy resistanceAnti-diabetic agentsAdjuvant roleColon cancerSurvival rateAnti-malarialsPromising therapiesDrug repurposingIncreased life expectancyPoor dietCancerGeneral populationAnti-hypertensiveDrugAnti-inflammatoryComorbiditiesAHCC®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
Park HJ, Boo S, Park I, Shin MS, Takahashi T, Takanari J, Homma K, Kang I. AHCC®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. Frontiers In Immunology 2022, 13: 875872. PMID: 35514996, PMCID: PMC9066372, DOI: 10.3389/fimmu.2022.875872.Peer-Reviewed Original ResearchConceptsDual immune checkpoint blockadeImmune checkpoint blockadeAnti-tumor effectsCheckpoint blockadeBearing miceStandardized extractTumor growthMC38 tumor-bearing miceGut microbiomePD-1/CTLATumor-infiltrating CD8Cell functionCancer bearing miceT cell functionKi-67 expressionImmune cell functionMurine colon cancerTumor bearing miceTumor-bearing miceTreatment of cancerTreatment strategiesT cellsTherapeutic effectGranzyme BColon cancerAppendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology.
Salazar MC, Canavan ME, Chilakamarry S, Boffa DJ, Schuster KM. Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. Journal Of The American College Of Surgeons 2022, 234: 1082-1089. PMID: 35703801, DOI: 10.1097/xcs.0000000000000172.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerNational Cancer DatabaseAppendiceal cancerColon cancerAcute appendicitisNonoperative managementCancer DatabasePatients 49 yearsPatients 18 yearsArea of residenceLogistic regression modelsAppendiceal histologyPatients 40Appendectomy specimensPatient ageCarcinoid tumorsAppendiceal carcinoidsCancer incidenceCancer histologySmall studyAge groupsCancerCarcinoidsLogistic regressionHistology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply